


41

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Patent Application of

IBA et al.

Atty. Ref: 423-59

Appln. No. 09/800,520

Group Art Unit: 1636

Filed: March 8, 2001

Examiner: G.G. Leffers, Jr.

FOR: PROCESS FOR PREPARING RETROVIRUS VECTOR FOR GENE THERAPY

\* \* \* \* \*

**INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97(c)**

March 4, 2004 **RECEIVED**

U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

**MAR 09 2004**

Sir:

Attached is a Form PTO-1449 listing the enclosed documents and the European Search Report for the related foreign patent application EP 97947924.3.

In lieu of certification, the Rule 17(p) fee is submitted herewith. But if this fee is missing or inadequate, please charge the deficiency to our Deposit Account No. 14-1140 (Client-Matter No. 423-59) for which purpose this paper is submitted in duplicate.

This information disclosure statement is intended to be in full compliance with the rules, but should the Examiner find any of its required contents to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under 37 CFR § 1.97(f), to enable Applicants to comply fully. In particular, if any of the listed documents are missing or incomplete, please contact the undersigned who will provide another copy.

03/08/2004 HMEKONEN 00000039 09800520

01 FC:1806

180.00 OP

823470


As provided by 37 CFR §§ 1.97(g) and (h), no inference should be made that this information and the listed references are prior art merely because they have been submitted for consideration. Furthermore, no representation is being made that a search has been conducted or that this statement encompasses all possible material information.

Consideration of the foregoing and enclosures, as well as the return of a copy of the Form PTO-1449 with the Examiner's initials per MPEP § 609, are earnestly solicited. The Examiner is invited to contact the undersigned if further information is needed.


Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_

  
Gary R. Tanigawa  
Reg. No. 43180

1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100


**INFORMATION DISCLOSURE  
CITATION**

ATTY. DOCKET NO.

423-59

APPLICANT

IBA et al.

FILING DATE

March 8, 2001

APPLN. NO.

09/800,520

GROUP

1636

(Use several sheets if necessary)

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AR						
BR						
CR						
DR						
ER						
FR						

RECEIVED

MAR 09 2004

**FOREIGN PATENT DOCUMENTS**

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
GR					
HR					
IR					
JR					
KR					
LR					
MR					
NR					
OR					

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

PR	Lagnado et al. "AUUUA is not sufficient to promote poly(A) shortening and degradation of an mRNA: The functional sequence within AU-rich elements may be UUAUUUA(U/A)(U/A)" Mol. Cell. Biol. 14:7894-7995 (1994)
QR	Schuler et al. "GM-CSF and oncogene mRNA stabilities are independently regulated in <i>trans</i> in a mouse monocytic tumor" Cell 55:1115-1122 (1988)
RR	European Search Report for EP 97947924.3 dated February 5, 2004
SR	
TR	
UR	
VR	
WR	
XR	
YR	
ZR	
AAR	
BBR	
CCR	
DDR	
EER	
FFR	
*Examiner	